Compounded Injectable Medication Recalled Due to Sterility Assurance Failure
Olympia Compounding Pharmacy is recalling 205 vials of Formula F9 injectable medication nationwide due to lack of assurance of sterility. The FDA has classified this as a Class II recall.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable medication where the manufacturer lacks assurance of product sterility. While no illnesses or injuries have been reported, the theoretical risk of infection from use of a product with unconfirmed sterility represents a significant potential harm to patients.
Plain-English summary
Olympia Compounding Pharmacy is recalling Formula F9, a compounded injectable medication supplied in multi-dose 10 mL vials (NDC 73198-0004-10). The product contains Papaverine 0.9 mg/mL, Phentolamine 0.1 mg/mL, PGE 20 mcg/mL, and Atropine 0.01 mg/mL.
The recall was initiated because the manufacturer lacks assurance that the product meets sterility standards required for injectable medications. The affected lot is B24G02-22 with a beyond-use date of February 2, 2023.
The product was distributed nationwide throughout the United States, Puerto Rico, and the U.S. Virgin Islands. Approximately 205 vials were affected by this recall.
The recalled product
- Product
- Formula F9 Papaverine 0.9 mg/mL Phentolamine 0.1 mg/mL PGE 20 mcg/mL Atropine 0.01 mg/mL, Multi-Dose 10 mL vial, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835, NDC 73198-0004-10
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable / Compounded
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: B24G02-22 BUD: 2/2/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27